635712-99-1

Basic information

• Product Name: 6-(BENZYLOXY)NICOTINALDEHYDE
• Synonyms: 6-(BENZYLOXY)NICOTINALDEHYDE
• CAS NO: 635712-99-1
• Molecular Formula: C₁₃H₁₁NO₂
• Molecular Weight: 213.23
• EINECS: 604-604-1
• Mol File: 635712-99-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 6-(BENZYLOXY)NICOTINALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(BENZYLOXY)NICOTINALDEHYDE(635712-99-1)
• EPA Substance Registry System: 6-(BENZYLOXY)NICOTINALDEHYDE(635712-99-1)

Safety Data

• Hazardous Substances Data: 635712-99-1(Hazardous Substances Data)

Usage

General Description

6-(BENZYLOXY)NICOTINALDEHYDE is a chemical compound with the molecular formula C16H15NO2. It is a derivative of nicotinaldehyde, and its structure includes a benzyl group attached to the oxygen atom of the aldehyde functional group. 6-(BENZYLOXY)NICOTINALDEHYDE is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and bioactive molecules. It has also been studied for its potential biological activities, including its role as a chemoattractant for leukocytes and its potential anti-inflammatory properties. Additionally, 6-(BENZYLOXY)NICOTINALDEHYDE has been investigated for its potential use as a ligand in coordination chemistry and as a precursor for the synthesis of diverse heterocyclic compounds.

Upstream product

• 83664-33-9 2-(benzyloxy)-5-bromopyridine 
• 144-55-8 sodium hydrogencarbonate 
• 100-39-0 benzyl bromide 
• 106984-91-2 2-hydroxypyridine-5-carboxaldehyde 
• 624-28-2 2,5-dibromopyridine 
• 100-51-6 benzyl alcohol 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 943145-98-0 2-Benzyloxycarbonylamino-3-(6-benzyloxy-pyridin-3-yl)-acrylic acid methyl ester 
• 106984-91-2 2-hydroxypyridine-5-carboxaldehyde 
• 1402148-74-6 C₁₄H₁₀F₃NO₂ 
• 1391828-89-9 C₁₄H₁₂F₃NO₂ 
• 945002-09-5 C₂₀H₁₇N₅O₂ 
• 936342-38-0 2-benzyloxy-5-((E)-2-nitro-vinyl)-pyridine 
• 791-28-6 Triphenylphosphine oxide 

Relevant articles and documents

HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA

There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof,wherein the ring containing Q1to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

Pyridone derivatives carrying radical moieties: Hydrogen-bonded structures, magnetic properties, and metal coordination

Pyridone derivatives carrying radical moieties were prepared, namely a nitronyl nitroxide derivative 5-(4′,4′,5′,5′- tetramethylimidazoline-3′-oxide-1′-oxyl)-2(1H)-pyridone (1) and a verdazyl derivative 1,5-dimethyl-3-[2(1H)-pyridone]-6-oxoverdazyl (2). In the solid state, 1 and 2 form, via N-H?O intermolecular hydrogen bonds between the pyridone moieties, a zigzag one-dimensional chain structure and a cyclic dimer structure, respectively. These compounds exhibit antiferromagnetic intermolecular interactions. Mononuclear metal complexes [M(hfac) 2(1)2] (M = CuII, MnII; hfac = bis(hexafluoroacetylacetonate)) were prepared in which trans-[M(hfac) 2] are coordinated with the carbonyl oxygen of the pyridone ligands. Cyclic hydrogen bonds between the mononuclear units result in the formation of one-dimensional chains. Small antiferromagnetic (for CuII) and ferromagnetic (for MnII) exchange interactions between the metal ion and the ligands were observed.

INHIBITORS OF TNFα, PDE4 AND B-RAF, COMPOSITIONS THEREOF AND METHODS OF USE THEREWITH

Provided herein are compounds having TNFα and/or PDE4 and/or B-RAF inhibitory activity, and compositions thereof. In particular, provided herein are compounds of the formula (I) and pharmaceutically acceptable salts, solvates, hydrates, clathrates, stereoisomers, polymorphs and prodrugs thereof, wherein Ar, R1, R2, R3, R4, n and Z are as described herein. Further provided herein are methods for treating or preventing various diseases and disorders by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors. In particular, provided herein are methods for preventing or treating cancer, inflammatory disorders, cognition and memory disorders and autoimmune disorders, or one or more symptoms thereof by administering to a patient one or more TNFα and/or PDE4 and/or B-RAF inhibitors.